A single patient developed acute ischemic priapism after reported Melanotan II use and required surgical management.
What the researchers measured
The report describes the presentation, response to initial procedures, and subsequent decompression.
How to read this evidence
A report of individual cases can highlight a possible safety signal. It cannot show how often an event occurs or prove that the peptide caused it.
Results in context
This is a clinically important adverse-event report, rather than an estimate of frequency or proof of safety in people without that event.
What this does not establish
One case can identify a possible adverse event but cannot determine its frequency or prove causation. Product identity and exposure are not equivalent to a controlled trial.
Publication & source
Why this paper is included
A patient case reports priapism after melanotan II injection; a case report cannot estimate incidence.
Publication indexing
Case Reports · Journal Article
Source checked
October 4, 2026. Years follow journal issues; online-first dates may differ.